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1. Introduction 
Prostate cancer continues to be one of the most common fatal cancers in men (Jemal et al., 
2010). The comprehensive understanding of the etiology of this disease is however, far from 
complete because of multitude of genetics and environmental factors involved in the 
development of this disease (Deutsch et al., 2004; Giovannucci, 2001). One characteristic 
feature of the prostate gland is its unique ability to accumulate high concentrations of zinc, 
which may otherwise be toxic to other tissues (Costello & Franklin, 1998). For reasons 
primarily still unknown, cancerous prostate cells somehow lose its ability to accumulate 
intracellular zinc concentrations. This is based on consistent observations of low zinc 
concentrations in malignant prostate tissues as compared to normal prostate and benign 
prostatic hyperplasia tissues (Feustel & Wennrich, 1984; Ho, 2004; Vartsky et al., 2003; 
Zaichick et al., 1997). These findings thereby, imply a potential importance of zinc in the 
pathogenesis of prostate cancer.  
It is suggested that dietary zinc supplementation protects against oxidative damage, reduces 
cancer risk (Ho, 2004) and has therapeutic potentials against prostate cancer (Franklin & 
Costello, 2007). Epidemiologic studies, however, provided contradictory findings on the 
effectiveness of zinc in prevention against prostate cancer. While there are studies that 
showed zinc reduces the risk of developing prostate cancer (Key et al., 1997; Kristal et al., 
1999), others showed that advanced prostate cancer is associated with high intake of zinc and 
potentiate the development of benign prostate hyperplasia (BPH) and progression towards 
cancer (Gallus et al., 2007; Lagiou et al., 1999; Lawson et al., 2007; Leitzmann et al., 2003; 
Moyad, 2004). Various mechanisms have been proposed to explain how high zinc regulates 
prostate health and indirectly, how its absence or low concentration could have contributed to 
the occurrence of prostate cancer. Restoration of high zinc to cancerous prostate tissues has 
been shown to inhibit prostate cancer cells proliferation (Feng et al., 2002; Feng et al., 2000; 
Iguchi et al., 1998; Liang et al., 1999) and invasion (Ishii et al., 2004; Ishii et al., 2001a; Ishii et al., 
2001b; Uzzo et al., 2006). In contrast, there are studies which showed that zinc under non-
physiological conditions could promote cancer cell growth and invasion (Boissier et al., 2000; 
Nemoto et al., 2000; Wong & Abubakar, 2008a; Wong & Abubakar, 2010).  
Because of the diverse roles of zinc in cell signaling, the exact pathways and genes affected by 
the absence or presence of high zinc concentrations in prostate cancer cells remain unraveled. 
In an attempt to further understand the complexicity of the role of zinc in prostate cancer, this 
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chapter will discuss issues related to the regulatory roles of zinc in normal prostate, the 
consequences of losing this regulatory role in the malignant cells and the implications of zinc 
supplementation in the cancer cells. 
2. Zinc and human health 
Zinc is an essential trace element, critical for diverse biological functions in the human body. 
Its importance in humans was not discovered until 1961 where zinc deficiency was found to be 
the cause of growth retardation and hypogonadism in Iranian and Egyptian patients (Prasad 
et al., 1961; Prasad et al., 1963). Meat, poultry, oyster, dairy products, legumes and cereals are 
food rich in zinc. However, phytates, which are present in some cereals and legumes can 
reduce the bioavailability of zinc by inhibiting absorption of zinc in the intestines (Sandstrom, 
1997; Wise, 1995). The recommended dietary allowance (RDA) for daily intake of zinc in 97-
98% healthy individuals is 8 mg/d for women, 11 mg/d for men, 11-12 mg/ml for pregnant 
and lactating women. Children from 1-3 years old, 4-8 years and 9-13 years old require 3, 5 and 
8 mg/d of zinc, respectively (Food and Nutritional Board of Medicine, 2010a). The tolerable 
upper intake level (UL), defined as the maximal daily intake unlikely to cause adverse health 
effects is 40 mg/d for adults. For children of 1-3, 4-8 and 9-13 years old, ULs are 7 mg/d, 12 
and 23 mg/d, respectively, (Food and Nutritional Board of Medicine, 2010b). 
Deficiency of zinc is associated with significant health problems. Early manifestations of 
zinc deficiency include decreased immunity resulting in increased susceptibility to 
infections such as diarrhea, common cold, acute lower respiratory infection and malaria. 
Zinc-deficient individuals also display dermatitis, delayed wound healing and alopecia. 
Prolonged deficiency leads to retardation of growth, genital development, hypogonadism 
and impaired neuropsychological functions (Prasad, 2008). Zinc deficiency in pregnancy 
retards fetal growth and postnatal development, causes neural tube defects and premature 
birth but the use of zinc supplementation in women still requires further studies (Osendarp 
et al., 2003; Uriu-Adams & Keen, 2010).  
Zinc supplements are found in the forms of zinc gluconate, zinc sulfate, and zinc acetate, 
where the percentage of elemental zinc can varies (Haase et al., 2008). Studies have shown that 
supplementation with zinc corrects growth and gonadal development, improves immune 
functions and hastens recovery from diarrhea, common cold, acute lower respiratory infection 
and malaria (Black, 2003; Fischer Walker & Black, 2004). It is also used to treat genetic 
disorders such as acrodermatitis enteropathica (Maverakis et al., 2007) and Wilson’s disease 
(Brewer, 2001). Zinc excess can induce copper deficiency and it is used in Wilson’s disease to 
interfere with uptake of copper and subsequently reduce excessive copper accumulation. 
While zinc supplementation may be beneficial in certain conditions excessive zinc intake can 
pose serious health risks. Acute zinc toxicity causes gastrointestinal-related symptoms such 
nausea, vomiting, tenesmus and diarrhea (Brown et al., 1964). Chronic zinc toxicity can lead to 
copper deficiency and its related hematological and neurological manifestations (Maret & 
Sandstead, 2006). Chronic high intake of zinc can also cause abnormalities of genitourinary 
functions (Johnson et al., 2007).  
3. Zinc homeostasis and transport 
Total zinc in human body is about 2-3 g for a 70 kg adult (Wastney et al., 1986). Ninety 
percent is incorporated in the muscle, most of which are poorly exchangeable and tightly 
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bound to high molecular weight ligands such as metalloenzymes, metalloproteins, 
nucleoproteins and nucleic acids. The remaining 10% of zinc is readily exchangeable and 
loosely bound to amino acid and citrate (Frederickson, 1989; Outten & O'Halloran, 2001). 
This pool of zinc is found in plasma, liver and bone and is metabolically active, rapidly 
exchanged and sensitive to changes in the bioavailability of zinc in the diet. The prostate 
gland, pancreas, adrenal gland, certain areas of the brain, inner ear and eye, skin, nails, hair, 
red and white blood cells are known to accumulate high concentrations of zinc (Tapiero & 
Tew, 2003).  
The concentrations of zinc are strictly regulated in vivo because dysregulation of zinc 
homeostasis can result in pathogenic consequences. Approximately 30-40% of intracellular 
zinc is localized in the nucleus, 50% in the cytosol and cytosolic organelles and the 
remainder are associated with cell membranes (Vallee & Falchuk, 1993). Zinc transporters 
play important roles in maintaining zinc homeostasis, as zinc ions are hydrophilic and do 
not cross cell membranes by passive diffusion (Cousins & McMahon, 2000). There are two 
known families of zinc transporters i.e. the ZIP (Zrt/Irt-like proteins (SLC39A)) family and 
the cation diffusion facilitator/Zinc transporter (CDF/ZnT (SLC30A)) family. At least 15 
members of the ZIP family (Zn2+-regulated metal transporter) (Cousins et al., 2006) and 10 
members from the ZnT family (Eide, 2004) are found in mammalian cells. ZnT transporters 
regulate zinc efflux from cells or into intracellular vesicles, hence, reduce intracellular zinc 
availability, whereas ZIP members of the ZIP family participate in the transport of zinc, iron, 
and/or manganese. The human ZIP1, ZIP2, and ZIP4 proteins are involved in zinc uptake 
across the plasma membrane of various cell types (Eide, 2004).  
4. Major functions of zinc 
4.1 Structural and catalytic functions 
Zinc has structural, catalytic and regulatory functions. It is a structural element found in 
many enzymes essential for DNA synthesis, transcription, aminoacyl-tRNA synthesis and 
ribosomal functions. It is found in zinc finger motifs of more than two thousands of 
transcription factors where these motifs provide a platform for interaction with DNA or 
other proteins (Vallee et al., 1991). Zincs are also found in LIM domains in proteins 
important for cytoskeletal organization, organ development and oncogenesis (Kadrmas & 
Beckerle, 2004). Zinc regulates cell proliferation and differentiation by modulating nucleic 
acid metabolisms and protein synthesis. It also controls cell growth by activating, 
transporting and modulating growth hormone, insulin-like growth factor-1, prolactin, 
testosterone and other steroid hormones (Costello et al., 1999; Ozturk et al., 2005; Prasad et 
al., 1996; Turgut et al., 2005). Zinc, unlike the highly reactive copper and iron, does not 
participate in redox reactions (Berg & Shi, 1996). The incorporation of zinc into proteins 
instead of these highly reactive elements helps prevent the generation of free radicals (Ho, 
2004). Zinc, hence, has anti-oxidant activities. It maintains proper folding, stability and 
activity of zinc-dependent enzymes by protecting these enzymes from free radicals attacks 
(Coleman, 1992). Some of the zinc-dependent enzymes include superoxide dismutase, 
carbonic anhydrase, alkaline phosphatase, glutamic dehydrogenase, nucleotidase, 
carboxypeptidase A, retinal dehydrogenase and angiotensin-converting enzymes. 
Intracellular zinc also protects several compounds from oxidative damage and these include 
citrate in the prostate gland (Omu et al., 1998) and insulin in the secretory granules of the 
islet beta cells (Zalewski et al., 1994). In addition, zinc exerts its anti-oxidant abilities 
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indirectly by maintaining an adequate level of the free radical scavengers such as 
metallothioneins (MTs) (Prasad, 1993; Tapiero & Tew, 2003). It also stabilizes cell membrane 
structure such as that of the red blood cells (Hennig et al., 1996) and sperm cells (Omu et al., 
1998). Zinc-bound melanin granules of the skin, choroids, iris, retina, photoreceptors of the 
eye also provide protection against oxidative damage and apoptosis (Borovansky, 1994).  
4.2 Zinc and immunity 
Zinc is critical for immune function and is involved in many aspects of the immune system 
(Shankar & Prasad, 1998). Deficiency of zinc causes dysfunction of cells involved in innate 
immunity such as macrophages, neutrophils and natural killer (NK) cells and affects 
phagocytosis, intracellular killing, cytokine production, complement activity and delayed-
type hypersensitivity. Zinc is also important for gene regulation in T lymphocytes. It 
activates pituitary growth hormone and thymulin, the thymic hormone that stimulates 
division, differentiation and maturation of T-cells, lymphocyte proliferation and cytotoxic 
activity of natural killer cells (Baum et al., 2000; Prasad, 1998). It also modulates the function 
of T-helper cells by regulating lymphokines, interleukin-2 (IL-2), interferon-gamma (IFN-) 
and tumour necrosis factor-alpha (TNF-) in response to invasion of pathogens (Baum et al., 
2000). It is also known that zinc helps in tissue repair and wound healing by stimulating 
keratinocyte proliferation and migration to the injured area (Tenaud et al., 2000) and 
scavenges proinflammatory cytokines-produced nitric oxide to prevent tissue damage 
(Yamaoka et al., 2000).  
4.3 Zinc in cell signaling 
Zinc is involved in many aspects of cell signaling, ranging from signal recognition, second 
messenger metabolisms to the regulation of gene expressions. It regulates signaling 
processes by directly modulating the activities of kinases, phosphatases, and transcription 
factors (Beyersmann & Haase, 2001) or acting on its own as an intracellular secondary 
messenger (Fukada et al., 2011; Yamasaki et al., 2007). Zinc initiates the signaling cascades 
by stimulating the activation of several receptors and ion channels and these include 
epidermal growth factor receptor (EGF-R) (Wu et al., 1999); insulin growth factor-1 receptor 
(IGF-1-R) (Haase & Maret, 2005); Gamma-AminoButyric Acid (GABA) receptor (Parviz & 
Gross, 2007); N-methyl-D-aspartate (NMDA) channels of the neuronal cells (Smart et al., 
2004); voltage-gated Ca2+ (Magistretti et al., 2003), the calcium permeable -amino-3-
hydroxy-5-methyl-4-isoxazole-propionate (AMPA) channels (Blakemore & Trombley, 2004), 
transient receptor potential ankyrin (Hu et al., 2009) and ATP-sensitive K+ channels (Prost et 
al., 2004). It also affects the activities of several second messengers. It is shown that zinc 
inhibits cyclic adenosine monophosphate (cAMP) signaling (Klein et al., 2002) and elevates 
cyclic guanosine monophosphate (cGMP) levels (Watjen et al., 2001).  
Zinc regulates the transcription of genes important for cell proliferation and differentiation 
by modulating transcription factors such as metal response element-binding transcription 
factor-1, MTF-1 (Langmade et al., 2000); Egr-1 (Adamson et al., 2003); AP-1 and NF-B 
(Herbein et al., 2006; Uzzo et al., 2006); Jun and ATF-2 (Samet et al., 1998). Among these, 
MTF-1 to date is the best-characterized zinc-activated transcription factors. MTF-1 responds 
acutely to changes in intracellular zinc concentrations by binding with zinc and translocates 
to nucleus. It then activates genes transcription by binding to promoters of other known 
zinc-responsive genes such as metallothioneins (MTs) and zinc transporter, ZnT-1 that 
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regulate intracellular zinc concentrations (Langmade et al., 2000). Other zinc finger 
transcription factors such as Egr-1, AP-1 and NF-B are important for the regulation of 
genes that control cells proliferation. Deregulation of these transcription factors contributes 
to cancer cells proliferation, metastasis and angiogenesis. How zinc affects the regulation of 
these transcription factors and their outcomes, however, varies. It is shown in a number of 
studies, that zinc at different concentrations activate or suppress the activities of NF-B in 
different cell lines resulting in different cellular responses (Kim et al., 2007; Uzzo et al., 2006; 
Uzzo et al., 2002).  
Zinc modulates kinases and phosphatases of major cells signaling pathways. A number of 
studies showed that zinc stimulates EGF receptor phosphorylation and activates members 
of the MAPKs family such as ERK (Hansson, 1996; Klein et al., 2006; Samet et al., 1998; Uzzo 
et al., 2006) and p38 kinase (Huang et al., 1999; Wu et al., 1999; Wu et al., 2005) activities in 
prostate cancer cells, murine fibroblasts, human bronchial epithelial cells, human airway 
epithelial cells and mouse cortical cells. Zinc also induces the phosphorylation of p70S6 
kinase in murine fibroblasts, c-jun N-terminal kinase (JNK) in mouse cortical cells through 
phosphatidylinositol 3-kinase (P13K) signaling pathway (Eom et al., 2001; Kim et al., 2000), 
protein kinase C (PKC) activation (Csermely et al., 1988), protein kinase B (PKB) and 
glycogen synthase kinase (GSK)-3 activities in neuroblastoma cells (An et al., 2005). A 
number of studies also described the role of zinc in the modulation of phosphatases. 
Treatment of the human airway epithelial cells and C6 rat glioma cells with zinc increased 
protein tyrosine phosphorylation by inhibiting phosphatases such as PTP1B and SHP-1 
(Haase & Maret, 2005) and zinc also inhibits the dual-specificity phosphatase VHR (Kim et 
al., 2000). These findings illustrate the extensive involvement of zinc on cellular signaling 
pathways and genes transcription. Balanced zinc homeostasis, therefore is vital for normal 
cell growth and differentiation; and deviations from optimal zinc levels may contribute to 
pathophysiologic consequences observed in many zinc-related diseases. Most of these zinc-
affected pathways are also deregulated in many types of cancer and this further highlights 
the importance of zinc homeostasis in oncogenesis. 
5. Zinc and the prostate gland 
The human prostate gland is divided into three distinct morphological regions which 
include the peripheral, central and transition zones (McNeal, 1981). The peripheral zone 
contains the majority of the glandular tissues present in the normal prostate and accounts 
for 70% of the volume in the young adult prostate. The central zone consists of larger acini 
and has a more complex ductal branching while the transition zone comprises of glands 
lobules with shorter ducts in comparison to those in the peripheral zone. The central and 
transition zones account for 25% and 5% of the prostate volume, respectively.  
The normal peripheral zone of the prostate gland accumulates the highest concentrations of 
zinc in comparison to other soft tissues of the body (Kar & Chowdhury, 1966; Lahtonen, 
1985). The ability to accumulate zinc in the peripheral zone is due to the presence of highly 
specialized secretory epithelial cells that is not found in the central zone of the prostate. 
hZIP1 transporter is an important transporter for uptake from the circulation and 
accumulation in the prostate gland (Costello et al., 1999; Desouki et al., 2007) while hZIP-2 
and hZIP-3 retain zinc in the cellular compartment (Desouki et al., 2007). 
hZIP1 transporters are downregulated in adenocarcinoma cells and in prostate intra-
epithelial neoplastic loci (PIN) (Rishi et al., 2003). This causes not only a decrease in zinc 
www.intechopen.com
 
Prostate Cancer – From Bench to Bedside 
 
428 
uptake (Franklin et al., 2005a; Franklin et al., 2003; Franklin et al., 2005b) but also reduces the 
capacity to accumulate zinc (Huang et al., 2006). The downregulation of hZIP1 is also 
associated with high prostate cancer risk in African American male population in 
comparison with Caucasians (Rishi et al., 2003). hZIP2, hZIP3 and ZnT4 are also found 
downregulated in malignant tissues in comparison to nonmalignant and Benign prostatic 
hyperplasia (BPH) tissues (Beck et al., 2004; Desouki et al., 2007). These findings collectively 
suggest that alterations of intracellular zinc due to changes in zinc transporters expression 
are associated to the development prostate cancer. It is suggested that human ZIP1, ZIP2 
and ZIP3 genes may be tumor suppressor genes (Desouki et al., 2007) and zinc may be a 
tumor suppressor agent (Franklin & Costello, 2007). 
5.1 Association of zinc with prostate cancer 
It is still unclear of the role of zinc in malignant diseases but abnormal levels of zinc in 
serum of cancer patients and malignant tissues are widely reported. Serum zinc levels are 
increased in melanoma patients (Ros-Bullon et al., 1998) but more often, reduced serum zinc 
levels are reported in breast (Sharma et al., 1994; Yucel et al., 1994), gallbladder (Gupta et al., 
2005), lung (Diez et al., 1989; Issell et al., 1981), Hodgkin's disease (Cunzhi et al., 2001), 
colorectal (Gupta et al., 1993), neck (Buntzel et al., 2007), leukemia (Zuo et al., 2006) and 
thyroid (Al-Sayer et al., 2004) cancer patients. Elevated zinc levels in malignant tissues are 
observed in breast (Margalioth et al., 1983), intestinal (Kucharzewski et al., 2003), metastatic 
nasopharyngeal (Bay et al., 1997) cancers but are decreased in kidney carcinoma tissues 
(Margalioth et al., 1983). It is also high in bone marrow of patients with non-Hodgkin 
lymphomas (Schmitt et al., 1993). In prostate cancer, decreased zinc levels are consistently 
observed in malignant tissue samples from different populations and at various stages of 
malignancy (Vartsky et al., 2003; Zaichick et al., 1997). Analysis of malignant prostate tissues 
showed a 60-70% reduction of zinc levels in comparison to those of the normal peripheral 
zone tissues (Zaichick et al., 1997). The plasma zinc level between patients with malignancy 
is also significantly lower than normal patients (Goel & Sankhwar, 2006). 
5.1.1 Epidemiologic studies 
It is reported that dietary zinc supplementation protects against oxidative damage, reduces 
cancer risk (Ho, 2004) and is beneficial against prostate tumorigenesis (Franklin & Costello, 
2007). Findings from several epidemiologic studies, however, attain no consensus on the 
effectiveness of zinc against prostate cancer, partly because of differences in experimental 
design, amount of zinc administered and methods in determining plasma/serum zinc status 
(Haase et al., 2008). Several studies showed that there are either no beneficiary effects of zinc 
or there are no potential adverse effects of dietary zinc on prostate cancer risk (Andersson et 
al., 1996; Kolonel, 1996; Vlajinac et al., 1997; West et al., 1991). In contrast, there are reports 
which concluded that zinc reduces prostate cancer risk (Epstein et al., 2011; Key et al., 1997;  
Kristal et al., 1999). Gonzalez et al. (2009) reported that dietary zinc was not associated with 
prostate cancer and 10-year average intake of supplemental zinc does not reduce the overall 
risk of prostate cancer. However, they found that risk of advanced prostate cancer decreases 
with greater intake of supplemental zinc in their VITamins And Lifestyle (VITAL) cohort 
study (Gonzalez et al., 2009). There are also reports that showed high zinc intake increases 
the risk of advanced prostate cancer (Gallus et al., 2007; Lawson et al., 2007; Leitzmann et al., 
2003) and higher intake of dietary zinc could also potentiate the development of BPH and 
progression towards cancer (Lagiou et al., 1999; Moyad, 2004). Although further studies are 
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required in this area, these reports nevertheless, raised concern for potential detrimental 
outcomes of long-term use of high zinc-supplements in men. 
5.1.2 In vitro studies 
The beneficial effects of zinc in prostate cancer intervention and treatment were investigated 
in vitro and in vivo but yielded contradictory observations as well. Several in vitro zinc 
studies showed that zinc inhibits prostate cancer cells proliferation and invasion through the 
induction of necrotic cell death and caspase-mediated mitochondrial apoptogenesis (Feng et 
al., 2002; Feng et al., 2000; Iguchi et al., 1998; Liang et al., 1999). Other suggested inhibitory 
mechanisms include increased levels of Bax or decreased Bcl-2 and survivin expression-
mediated apoptosis effect (Ku et al., 2010) and zinc-induced proteasomal degradation of 
HIF-1α, a protein often upregulated in tumors leading to more aggressive tumor growth 
and chemoresistance (Nardinocchi et al., 2010). In addition, zinc was reported to repress the 
metastatic potential of prostate cancer cells through various mechanisms. These include 
inhibition of NF-B activities (Uzzo et al., 2006), suppression of the invasive potentials of 
human prostate aminopeptidase N and urokinase-type plasminogen activator (Ishii et al., 
2001a; Ishii et al., 2001b) as well as inhibiting proteolytic activities of prostate specific 
antigen (PSA) (Ishii et al., 2004). In contrast, it is also reported that zinc promotes cancer cell 
growth by enhancing telomerase activity, an enzyme thought to be responsible for the 
continuous proliferation of tumor cells (Nemoto et al., 2000) and suppressing the inhibitory 
potential of bisphosphonates on tumor cell invasion (Boissier et al., 2000). Our studies also 
showed that restoration of high zinc for a prolonged period could only inhibit zinc 
proliferation transiently, after which the malignant cell growth was restored and acquired a 
more aggressive behaviour (Wong & Abubakar, 2008a; Wong & Abubakar, 2010).  
5.1.3 In vivo studies 
The association of zinc with prostate cancer and the therapeutic potentials of zinc in 
prostate cancer were also investigated in vivo (Table 1). Two early studies using xenograft 
mice inoculated with PC-3 cells (Feng et al., 2003) and PC-3-hZIP1 cells (Golovine et al., 
2008) showed that zinc treatment resulted in inhibition of tumor growth. Feng et al. (2003) 
showed that inhibition of tumor growth was due to zinc-induced apoptosis. Golovine et 
al. (2008) showed that overexpression of hZIP1 transporter in PC3 cancer cells resulted in 
increased zinc uptake, decreased tumor volume and inhibition of NFB activity which are 
usually high in PC3 cells at physiological zinc serum range (0.5–1.5 μg/ml). Direct 
intratumoral injection of zinc in mM range was also shown to halt prostate cancer cell 
growth in xenograft mice (Shah et al., 2009) but the practicality of using intratumoral 
administration in human remains in question. Prasad et al. (2010) used a more relevant 
mouse model i.e. transgenic adenocarcinoma of the mouse prostate (TRAMP) mice in 
their study to determine the role of zinc in the development of prostate cancer. TRAMP 
mice develop spontaneous autochtonous disease which enables studies on the 
transformation of normal prostatic cells, progression and metastasis of prostate cancer 
(Gingrich et al., 1996). These mice were given 0.85 ppm zinc (deficient), 30 ppm zinc 
(optimal) and 150 ppm zinc (high) for 14 weeks. Their results showed that prostate tumor 
weights were higher at both zinc-deficient and high zinc-supplemented mice which led 
them to suggest that zinc at optimal levels is preventive whereas at both deficient and 
higher levels it may enhance tumor growth (Prasad et al., 2010). 
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Animal models 
Zinc 
concentrations 
given 
Duration of 
treatment 
Findings References 
Nude mice 
inoculated with 
PC3  
0.25 µL/h 28 days 
(4 weeks) 
Inhibition of tumor 
growth 
Feng et al., 
2003 
C.B17/ICR-SCID 
mice inoculated 
with PC-3-hZIP1 
in the flank 
region 
2000 ppm 23 days 
(3.3 weeks) 
Decreased tumor 
volume 
Golovine  
et al., 2008 
NOD/SCID 
inoculated with 
PC3 cells in the 
dorsum of 
animals 
200 μL of 3 
mM zinc 
acetate per 
injection 
direct 
intratumoral 
injection every 
48 hours for a 
period of two 
weeks 
Halted prostate cancer 
cells growth  
Shah et al., 
2009 
TRAMP mice zinc deficient 
(0.85 ppm), 
optimal 
(normal) zinc 
(30 ppm) and 
high zinc (150 
ppm)  
14 weeks Significantly higher 
tumor weights in zinc-
deficient or high-zinc 
fed mice  
Prasad et al., 
2010 
Sprague-Dawley 
rats using N-
methyl-N-
nitrosourea 
MNU+ 
testosterone 
(MNU + T) 
100 ppm 3 times / week Fewer incidences of 
hyperplasia, dysplasia, 
and prostatic 
intraepithelial 
neoplasia in the ventral 
prostate zinc-treated 
mice  
Banudevi  
et al., 2011 
Sprague-Dawley 
rats using MNU+ 
cyproterone 
acetate + 
testosterone 
propionate 
227 mg/L 
(equivalent to 
227 ppm) 
20 weeks Increased incidence of 
prostate intraepithelial 
neoplasm  
Ko et al., 
2010 
Table 1. In vivo zinc studies using murine models 
To investigate the chemopreventive potential of zinc, Banudevi et al. (2011) treated prostate 
cancer induced Sprague-Dawley rats using N-methyl-N-nitrosourea MNU+ testosterone 
(MNU + T) with zinc (100 ppm) thrice a week. The zinc-treated mice showed fewer 
incidences of hyperplasia, dysplasia, and prostatic intraepithelial neoplasia in the ventral 
prostate compared to the non-treated group (Banudevi et al., 2011). They concluded that 
zinc may act as a potential chemopreventive agent in targeting prostate cancer. However, in 
another study on prostate cancer induced Sprague-Dawley rats using MNU+ cyproterone 
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acetate + testosterone propionate fed with zinc sulfate heptahydrate dissolved in drinking 
water (227 mg/L or 227 ppm) for 20 weeks, they found high dietary zinc increased 
intraprostatic zinc concentrations and promoted prostate intraepithelial neoplasm (Ko et al., 
2010). A much higher zinc and longer duration of treatment may be responsible for the 
observations made by Ko et al. (2010), it nevertheless suggests that high zinc treatment for a 
prolonged period may have detrimental outcomes.  
5.2 Mechanisms of zinc-induced prostate cancer pathogenesis 
It is established that zinc deficiency is associated with prostate cancer development based on 
the observation of significantly low/absence of zinc in cancerous prostate tissues and 
indirect evidences from in vitro and animal studies.  It remains to be unraveled whether the 
absence of zinc is a consequence of cells transformation or whether zinc deficiency directly 
contributes to transformation.  
A number of studies showed that zinc exerts both growth and metabolic effects on prostate 
cells and contribute to the development of prostate malignancy by altering citrate 
metabolism (Costello et al., 2004; Singh et al., 2006). It is reported in these studies that zinc 
inhibits in vitro cultured human prostate cell lines (LNCaP, PC3 and BPH-1) and rat ventral 
prostate epithelium cells proliferation by inducing mitochondrial apoptogenesis by 
releasing cytochrome c, which then activates subsequent caspase mediated-apoptotic 
cascading events leading to apoptosis. It is also shown that zinc inhibits the gene expression 
and activity of m-aconitase in prostate cells (Costello et al., 1997; Tsui et al., 2006). These 
findings led to the proposal that the presence of high zinc in normal prostate limits citrate 
oxidation via the Krebs cycle resulting in accumulation of high citrate levels for the secretion 
of prostatic fluids (Costello et al., 1997). In the transformed prostate cells, where zinc 
concentration is very low or absent, citrate oxidation can proceed via the Krebs cycle to 
generate ATP, thus, providing unlimited energy for malignant cells growth (Costello et al., 
2004; Costello & Franklin, 2006). Concurrently, as intracellular zinc decreases, the 
apoptogenic effects of zinc are also removed, hence encourages malignant cells proliferation 
(Costello et al., 2004). Based on these observations, these authors suggest that restoration of 
zinc to prostate may be an effective treatment for prostate cancer. 
Although the proposed mechanisms are plausible, it is also discussed above that zinc has 
diverse effects on cellular processes and mediates various signaling transduction pathways 
including those that are implicated in the development and progression of prostate cancer. 
This point was exemplified in another study that showed the involvement of zinc in Akt 
pathway (Han et al., 2009). Akt/protein kinase B (PKB) gene is amplified in cancerous prostate 
tissues and increase in its kinase activities are associated with hormone-resistant prostate 
cancer (Edwards et al., 2003). Activation of Akt pathway promotes the survival and protection 
of cancer cells from apoptosis by inhibiting downstream death proteins such as Bad, caspase-9 
and forkhead transcription factors (FHTF) (Cantley, 2002). Phosphatase and TENsin homolog 
(PTEN), a tumor suppressor, negatively regulate the phosphorylation of Akt and maintains it 
at basal level. Normal prostate cells accumulates high zinc and during zinc deficiency, Han et 
al. (2009) showed that Akt is hyperphosphorylated in prostate normal epithelial cells (PrEC) 
and led to Mdm2 phosphorylation and decreased nuclear accumulation of p53. This resulted 
in reduced tumor-suppressive effect of p53, hence, maintaining the progression of the cell 
cycle and promoting cell survival through an Akt-Mdm2-p53 signaling axis. In LNCaP 
prostate cancer cells where PTEN is deleted and mutated, Akt phosphorylation becomes 
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uninhibited. In zinc-deficient LNCaP cells, it is suggested that Akt phosphorylates p21, inhibits 
its nuclear entry and promotes cytoplasmic degradation. Hence, zinc-deficient LNCaP cells 
could survive and progress through the G0/G1 phase of the cell cycle. This study showed that 
zinc is important in maintaining the survival of normal prostate cells and in its absence, the 
malignant cells uses alternative pathway to promote cell survival instead.  
Difference in response to zinc between normal and malignant cells was also observed in our 
previous studies. We demonstrated an increasing percentage of senescent normal prostate 
PNT2 cells when treated with a high zinc concentration but this was not observed in LNCaP 
cells (Wong & Abubakar, 2008b). Hence, high zinc in the normal prostate regulates healthy 
prostate cell growth by maintaining senescence but this regulatory role is lost in zinc-deficient 
cancerous tissues. Han et al. (2009) also showed that cell growth was unchanged for LNCaP 
cells supplemented with high zinc although G2/M populations was depressed, which is 
similar to our observation (Wong & Abubakar, 2008a). Since there was no change in nuclear 
p21 level in high zinc-treated LNCaP cells in the study by Han et al., (2009), restoration of high 
zinc to LNCaP cells may have affected other pathways. We showed that restoration of high 
zinc to LNCaP for a longer period (5 weeks) resulted in upregulation of protein expression of 
Vaccinia H1-related (VHR) phosphatase, zeta chain-associated protein-70 (ZAP-70) kinase and 
phosphorylated extracellular signal-regulated protein kinase 1 and 2 (p-ERK 1 and 2) which 
declined after chelation of Zn2+, highlighting the possible association of zinc with VHR/ZAP-
70-associated pathways in the modulation of LNCaP prostate cancer cell growth.  
To further determine the effects of prolonged high zinc treatment on global gene 
expressions in LNCaP prostate cancer cells, we continuously cultured LNCaP cells for at 
least five passages over a 5 week period in growth medium supplemented with 
supraphysiologic concentrations of Zn2+ (Wong & Abubakar, 2010). Various methods were 
employed to demonstrate the intracellular accumulation of zinc and these are correlated 
with the cancer cell growth and proliferation. Specific gene expression analysis using 
microarray was used to examine the different gene expression levels and validated using 
quantitative real time polymerase chain reaction amplification. Using this approach it was 
observed that high intracellular zinc initially inhibited prostate cell growth and colony 
formation on soft agar. The inhibition, however, is transient as the cancer cell growth rate 
recovers to the pre-zinc treatment cancerous cell growth rate. Results from microarray 
studies using these prolonged high zinc-treated cells suggest that the recovery is 
accompanied by high expression of genes known to promote prostate cancer cell 
proliferation, migration and aggressiveness. Genes such as FASN, FAD, TACSTD1, FBL, 
ADRM1, E2F3, CD164 and STEAP1 are highly expressed. In addition, CD164, FBL and 
TACSTD1 were also found upregulated in increasing presence of high zinc in normal 
prostate PNT2 cells. Collectively, these findings suggest that zinc initially suppresses cell 
growth, perhaps by repressing the expressions of selected growth promoting genes but the 
ability of zinc to regulate these genes in the cancerous tissues are eventually lost, resulting in 
the superinduction of the expression of these genes which in turn promote the survival of 
the prostate cancer cells even when the intracellular zinc level is high. These observations, 
thus, support the epidemiologic findings that high zinc intake is associated with the 
progression to advanced aggressive prostate cancer. In another gene profiling study of 
normal human prostatic cell line HPR-1 and androgen-independent malignant prostate 
cancer PC3 cells treated with zinc (20 M) for 1-6 hours, it was also observed that zinc 
affects many genes involved in oncogenesis pathways although genes associated with zinc 
accumulation and zinc-induced apoptosis are also found responsive (Lin et al., 2009). In 
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their study, Fos, which codes for a transcription factor associated with AP-1, was 
dramatically up-regulated by short-term zinc treatment in PC-3 cells and up-regulation of c-
Fos protein is known to occur in advanced human prostate cancer (Ouyang et al., 2008). 
They also showed that expression of the Akt1 and PIK3 genes, associated with the Akt 
pathway, was dramatically upregulated in normal cells but remained unaffected in the 
cancer cells. However, the long-term effect of zinc on the expression of these genes is not 
known since cells were only treated for 6 hours in this study. This observation nevertheless 
supports the role of zinc in regulating malignancy promoting genes in normal cells but its 
control is lost in the cancerous tissues. The consequences following the loss of zinc 
regulation of cancer-promoting genes warrant further research. 
6. Conclusion 
Despite the contrasting reports on the effects of zinc on prostate cancer cells, these studies 
collectively affirmed the importance of zinc in the regulation of prostate health under 
normal physiologic conditions. Adverse consequences are apparent with zinc deficiency as 
well as with high zinc supplementation. The diverse effects of zinc on prostate cells reflects 
the immensity of zinc interactions with various cellular kinases, phosphatases, signaling 
transduction molecules and transcription factors in the regulation of normal cellular 
processes and immune responses, thereby also affecting those of the tumor cells and tumor 
microenvironment (John et al., 2010) once the normal cells transformed. Because of the 
extensive involvement of zinc in cellular signaling networks which includes its potential 
role in regulating cancer-promoting genes, simple restoration of high intracellular zinc 
concentration to the cancerous tissues may not be corrective. Instead, it may further fuel 
aberrant signaling in cancer cells leading to deleterious consequences. The use of zinc 
therapy based on its ability to induce apoptosis is effective perhaps when given 
intratumorally but dietary supplementation of zinc faces with issues of bioavailability and 
difficulties in achieving therapeutically meaningful dose in diseased prostate. The effects of 
chronic use of zinc still require further research with standardized zinc preparations, 
methods of zinc measurement, patient selection and statistical analysis to achieve a final 
consensus of the effectiveness of zinc in prostate cancer prevention and treatment. On the 
other hand, research focus on developing methods of using endogenous zinc (Ghosh et al., 
2010) for early detection and progression of prostate cancer in human as well as utilizing 
zinc-regulated genes for diagnosis or targeting them for treatment of prostate cancer may be 
more relevant in this regard.  
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